Saniona still the one to beat: Danish Biotech Weekly (28)

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, FluoGuide completed a 15 MSEK directed share issue, Zealand Pharma announced positive phase 1 results while Initiator Pharma finalized its buyback programme. Notably, Scandion Oncology rose nearly 50% without announcing any news.

Only 4 of the 20 listed, Danish biotech companies published news the past week. 7 of the 20 companies had a positive development in their share price for the week and 6 companies have had a positive share price performance year to date. Saniona continues to be the best performing stock this year with a price increase of more than 150%.

Company news the past week

Ascendis Pharma

No news the past week


No news the past week


No news the past week

CS Medica

No news the past week


No news the past week

Evaxion Biotech

No news the past week


No news the past week


FluoGuide completes a directed share issue raising SEK 15 million (Link)


No news the past week


No news the past week

Initiator Pharma

Finalization of share buyback program in Initiator Pharma (Link)

IO Biotech

No news the past week

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week


No news the past week

Zealand Pharma

Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 (Link)

Y-mAbs Therapeutics

No news the past week


Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET) (Link)



On average, the Danish biotech stocks delivered a positive share price performance last week of 1.9%. The overall positive return was largely driven by Scandion Oncology that became the best performing stock with an 49% increase without announcing any company specific news. FluoGuide completed a directed share issue of 15 MSEK while Zealand Pharma announced positive phase 1 results for ZP8936 with potential against obesity and diabetes. Neither news had any significant effect on the share prices of the two companies. Curasight became the worst performing Danish biotech stock with a 9% decrease after a strong share price performance. The best stocks year-to-date include Curasight A/S, Fluoguide A/S, and Saniona AB after soaring 112-152%. Overall the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 4.5%.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.